A New Generation of Early Warning Index for the Liver Cancer Rapid Detection Device for the Alpha Fetoprotein Heteroplasmon 1, What is the alpha fetoprotein heteroplasmon AFP-L3? The alpha fetoprotein produced by different lesions tissue contains different glycosyl, so does the affinity of it with the exogenous plant lectin. This can make a judgment on the source of AFP. It fall into AFP-L1, AFP-L2 and AFP-L3, amongwhich, AFP-L3 is the agglutinin of combined type and is peculiar for HCC cells of the primary liver cancer; whereas AFP-L1 mainly exists in benign liver disease, AFP-L2 come from pregnant women. Clinical study showed that AFP-L3 is the highly specific index of the primary liver cancer HCC. The positive rate of liver cancer AFP-L3 is 61%, the false positive rate of non-liver cancer patients is 1.6% -5%. This is with high accuracy rate for the diagnosis of liver cancer and can significantly improve the accuracy comparing the simple application of the total AFP (t-AFP). The establishment of the relation of AFP molecular sugar chain structure with cancer initiated the beginning of judging diseases according to the “qualitative ”change of the protein molecule sugar chain, it breakthrough the tradition on diagnosing tumor with the abnormal "quantity" of tumor markers in the field of experimental diagnosis. So, it is of important clinical value. 2, Why should the alpha fetoprotein heteroplasmon AFP-L3 be detected? AFP only has the relative specific diagnosis value for the liver cell cancer. After extensive and long-term clinical application, it showed certain limitations in the early diagnosis of liver cancer. In addition to liver cancer, other diseases can also cause the increase of AFP in serum, especially about 20% -40% of patients with chronic hepatitis and 20% -50% of patients with cirrhosis had the increase of AFP in serum. Whereas, these patients did not have the liver cancer, their AFP concentrations in serum could reach a very high level, or even exceed 1000 ng/ml after the acute deterioration of chronic hepatitis or cirrhosis. Therefore in order to improve the diagnosis of specificity and differentiate benign from malignant liver disease in clinical field, AFP ≥400 ng/ml is defined as the specific indicators of liver cancer, but this missed a lot of liver cancer with AFP ≤400 ng/ml. The reason is that only 25.7% patients from the early liver cancer had AFP ≥400 ng/ml. Therefore, in these high risk crowds, it is very difficult to give early warning for liver cancer with a single detection of AFP. 3, AFP-L3 is recognized as a new generation of liver cancer markers in the diagnosis, its main characteristics are: 1) Compared with imaging technology, the alpha fetoprotein heteroplasmon AFP-L3 can be detected earlier 9-12 months. When AFP L3 accounting for more than 10% in the gross of AFP, it suggested that the incidence of liver carcinoma is greater than 95%. Eliminating the limit of the negative results for the imaging examination can be helpful to identify the liver space-occupying lesions which are difficult to diagnose with imaging examination. 2) This method has no limit that AFP ≥ 400ng / ml is taken as the liver cancer diagnosis criteria, also, it needn’t take the dynamic observation for AFP content change, thereby shortening the time for the diagnosis of liver carcinoma. 3) Moreover, AFP-L3 has important significance in the assessment of effect and on prompting the recurrence of liver cancer; also, it is very helpful to the assessment of the malignant degree of tumor and tumor treatment options. 4) This method had been used in clinical testing in Japan for many years. FDA of the United States has ratified the biomarkers on October 2005 to use in clinical field and it marked the markers of liver cancer will be used in the world. Products provided: AFP-L3 test device 20 devices/kit